Introduction: regular weight individuals are less likely to have depressive symptoms than overweight or underweight persons. Depression is going to b to be the second reason of universal encumbrance disease by 2020. One of the reasons which causes depression is declining of BDNF which is considered as neurogenesis factor. brain-derived neurotrophic factor (BDNF) can be declined by increasing of stress. Additionally, the expression of BDNF in the brain can be raised by prolonged antidepressant treatment. The brain, serum, and plasma are considered the whereabouts of BDNF which has neurogenesis properties. Moreover, BDNF can cross blood brain barrier; then, brain BDNF levels can be reflected by serum BDNF levels. Some studies revealed the functions of BDNF in the mode of action of antidepressant drugs. Furthermore, some studies found that persons who have depression, have low BDNF levels. Proper treatment of antidepressants able to normalize BDNF levels.
Major depressive disorders might be treated by Zinc supplementation as an adjunctive therapy …show more content…
However, only animal models are experienced by researchers to figure out the impact of zinc supplementation on serum BDNF levels. Also, the impact of zinc supplementation on BDNF levels as an adjunctive therapy has been studied in human for depression treatment. Therefore, the purpose of this research was to investigate the impacts of zinc monotherapy on serum BDNF levels and depression severity in overweight or fat persons.
Methods:
Fifty overweight or obese participants are recruited and divided into two groups and given either 30mg zinc or placebo every day for 12 weeks. At baseline and in the last week, Beck depression inventory II (BDI II) was used to measure depression severity, enzyme-linked immunosorbent assay to measure serum BDNF, and atomic absorption spectrophotometry to measure zinc levels.
Major depressive disorders might be treated by Zinc supplementation as an adjunctive therapy …show more content…
However, only animal models are experienced by researchers to figure out the impact of zinc supplementation on serum BDNF levels. Also, the impact of zinc supplementation on BDNF levels as an adjunctive therapy has been studied in human for depression treatment. Therefore, the purpose of this research was to investigate the impacts of zinc monotherapy on serum BDNF levels and depression severity in overweight or fat persons.
Methods:
Fifty overweight or obese participants are recruited and divided into two groups and given either 30mg zinc or placebo every day for 12 weeks. At baseline and in the last week, Beck depression inventory II (BDI II) was used to measure depression severity, enzyme-linked immunosorbent assay to measure serum BDNF, and atomic absorption spectrophotometry to measure zinc levels.